Terumo (OTCMKTS:TRUMY) Sets New 1-Year Low – Here’s Why
by Tristan Rich · The Markets DailyTerumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s stock price hit a new 52-week low on Monday . The company traded as low as $14.03 and last traded at $14.5450, with a volume of 11905 shares changing hands. The stock had previously closed at $14.93.
Terumo Stock Performance
The company has a quick ratio of 1.46, a current ratio of 2.51 and a debt-to-equity ratio of 0.07. The stock has a market cap of $21.73 billion, a price-to-earnings ratio of 24.47 and a beta of 0.75. The stock’s fifty day moving average is $15.68 and its 200-day moving average is $16.82.
Terumo (OTCMKTS:TRUMY – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. Terumo had a return on equity of 9.39% and a net margin of 12.35%.The company had revenue of $1.86 billion during the quarter, compared to analysts’ expectations of $1.75 billion.
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.